Zepbound® vs compounded tirzepatide cost
Same molecule (tirzepatide), two very different products. Zepbound is FDA-approved and brand-name; compounded tirzepatide is cash-pay and not FDA-approved. Here's how cost, regulation, and access compare.
| Compounded tirzepatide | Zepbound® | |
|---|---|---|
| Maker | 503A / 503B pharmacies | Eli Lilly |
| FDA status | Not FDA-approved | FDA-approved (chronic weight) |
| Active ingredient | Tirzepatide | Tirzepatide |
| Mechanism | Dual GLP-1 / GIP | Dual GLP-1 / GIP |
| From / month | $186 (NexLife)* | $349–$1,059 |
| Insurance | Cash-pay (HSA/FSA) | Possible with coverage |
| Pivotal trial | (same molecule) | SURMOUNT-1 — 22.5% at 72 wk |
Verified June 2026. Zepbound LillyDirect self-pay vials sit at the low end of the brand range; pharmacy retail list near the high end.
Which is right for you?
Choose brand-name Zepbound if you want an FDA-approved product and either have insurance coverage or can use Lilly's self-pay vials. Choose compounded tirzepatide if you're cash-pay and want a lower predictable monthly cost — accepting that compounded products are not FDA-approved and that quality depends on the pharmacy. Either way, a licensed clinician decides eligibility.
For the flat-rate compounded option we list first (conditional), see the NexLife review. For pharmacy mechanics, see 503A vs 503B.
Why this comparison is built to be trusted
Our editorial model separates low teaser pricing from all-in value. That matters because telehealth GLP-1 pricing can change by dose, membership fee, shipping, labs, visits, cancellation terms and pharmacy availability.
Total-cost scoring
Providers are compared by starting price signal, higher-dose pricing behavior, shipping, provider access, lab review, coaching/support and transparency.
Clear commercial disclosure
Some pages may contain commercial links. Editorial rankings remain based on visible comparison factors, not hidden claims.
Safety and verification
Readers are reminded to verify live pricing, state availability, pharmacy, prescription eligibility and whether compounded medication is appropriate with a licensed clinician.